NCT03023215 is a NA clinical trial of Meditation in Meditation for Breast Biopsy, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT03023215?

NCT03023215 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT03023215?

Interventions in NCT03023215: Meditation, Electroencephalogram, Questionnaires, Heart Rate.

What condition does NCT03023215 study?

NCT03023215 studies Meditation for Breast Biopsy.

Is NCT03023215 still recruiting?

NCT03023215 is currently completed. Last updated 7 September 2023.

Last reviewed 2023-09-07 · How we verify

NCT03023215

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Brief Guided Relaxation for Women Undergoing Stereotactic Breast Biopsy

Completed NA Last updated 7 September 2023

What this trial tests

NA trial testing Meditation in Meditation for Breast Biopsy in 84 participants. Completed in 10 August 2022.

Timeline

26 October 2012

Primary endpoint
10 August 2022

10 August 2022

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	84
Start date	26 October 2012
Primary completion	10 August 2022
Estimated completion	10 August 2022
Sites	1 location across United States

Drugs / interventions tested

Meditation
Electroencephalogram
Questionnaires
Heart Rate

Conditions studied

Meditation for Breast Biopsy — all drugs for Meditation for Breast Biopsy →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, female only, with Meditation for Breast Biopsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this behavioral research study is to learn if taking part in guided relaxation programs helps to reduce anxiety and pain during stereotactic breast biopsy. The study will also examine whether the guided relaxation programs change brain activity, heart rate, and blood pressure.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

A Randomized Controlled Trial of Brief Mindfulness Meditation for Women Undergoing Stereotactic Breast Biopsy.
Ratcliff CG, Prinsloo S, Chaoul A, Zepeda SG, et al · · 2019 · cited 24× · PMID 30322793 · DOI 10.1016/j.jacr.2018.09.009
Who Benefits Most from a Brief Mindfulness Intervention to Reduce Anxiety during Stereotactic Breast Biopsy: The Moderating Effect of Trait Mindfulness, Spiritual Well-Being, and Distress Tolerance.
Ratcliff CG, Fowler S, Sinclair K, Prinsloo S, et al · · 2021 · cited 1× · PMID 39950152 · DOI 10.1007/s12671-020-01581-6

Verify or expand the search:

Other trials of Meditation

Trials testing the same drug.

NCT07534683 — Primed to Thrive: Investigating the Combined Impact of Mindfulness Education and Meditation Practice on Psychological an · NA · not yet recruiting
NCT03166072 — Health Education vs Meditation in Irreversible Age-Related Vision Loss Patients and Their Caregivers · NA · not yet recruiting
NCT07310992 — Effect of Meditation as an Adjunct to Cardiac Rehabilitation · NA · not yet recruiting
NCT07176013 — Immersive Virtual Reality Meditation in Voice Therapy · NA · enrolling by invitation
NCT06866288 — Belongingness in Nursing Through Mindfulness - BEING Mindful: A Pilot Study · NA · completed

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03023215 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 7 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03023215.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing